Colchicine does not work in Hand OA. Danish trial of 100 HOA pts (age 71 yrs) given placebo or COL 0.5 mg bid x 12wk. Finger pain improved –13·9 mm w/ colchicine vs –13·5 mm w/ PBO (NS). More adverse events w/ Colchicine (72% vs 44%) https://t.co/042BQcAFWf https://t.co/EldLmjVisD

• https://bit.ly/3qcqbth

Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS. *Erosions in 3 or more SIJ quadrants *BME in 4 or more SIJ quadrants *Fat lesions in 5 of more SIJ quadrants #RNL2023 @RheumNow https://t.co/T9iWLcNL8b https://t.co/BskCNz9Klj

• https://bit.ly/3owtGdv

Peresolimab's Potential in Rheumatoid Arthritis Peresolimab is a humanized IgG1 monoclonal antibody that acts as a PD-1 agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active RA. https://t.co/tBAC2vO31f https://t.co/pAknsSnnNT

• https://bit.ly/43bS9nk

U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/JFyiETe43S https://t.co/zGJKZ3l0d4

• https://bit.ly/3MZTat1

Join us for the final Tuesday Night Rheumatology of May. This webinar will feature highlights from these lectures followed by live audience Q & A: Methotrexate Use: 50 Yr. Perspective Myths vs Reality in RA Biosimilars - Back on the Agenda https://t.co/cqFNCRlGym https://t.co/fNS6cGBuDB

• https://bit.ly/3IE9tt3

Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/uR4ZwnPGiF

Ph 3 study 800 ICU pts w/ severe community acq pneumonia shows those on IV hydrocortisone had lower mortality at day 28 (6.2% vs 11.9%; P=0.006), less intubation (18% vs 29.5%), less vasopressors (15% v 25%) vs PBO; no Diff w/ infx rates or GI bleed https://t.co/BjIM8UJXZS https://t.co/389CZovrZm

• https://bit.ly/3MCWuJl

Watch our video presented by leading expert Dr. Michelle Petri to learn why complete renal response matters in #LupusNephritis. #SponsoredbyGSKUSMA https://t.co/XFZH5HprH4 https://t.co/PYfHy6uoZt

• https://bit.ly/3Iy8Cde

AxSpA is primarily a genetic disease - clusters in families, especially HLA-B27+ first degree relatives - genetic testing for asymptomatic relatives not recommended @RheumNow #RNL2023 https://t.co/WeNApLE5to https://t.co/zDzHfdmpCG

• https://bit.ly/3CepzWR

⚠️Beware not all bone marrow oedema =#AxSpA on MRI ! Signal seen in 17% volunteers at SIJs @DrPoddubnyy #RNL2023 https://t.co/c4gqnBzdnO https://t.co/kZiX8r62aY

• https://bit.ly/3Wx3Na2

Risk of familial AS is 19.4%, Reveille #RNL2023 ⁦@RheumNow⁩ https://t.co/7CzaXgqkPG https://t.co/KrmKGblVmd

• https://bit.ly/45sX6K7

"50 years ago in April we discovered HLA B27." Dr. Reveille #RNL2023 @RheumNow

Bone marrow edema was found in healthy individuals, Denis Poddubnyy #RNL2023 ⁦@RheumNow⁩ https://t.co/1n6E2QuGut https://t.co/y9Zzw6rdqN

• https://bit.ly/434zvxN

What to look for( MRI ), Denis Poddubnyy #RNL2023 ⁦@RheumNow⁩ STIR: inflammation T1 erosion, fatty changes VIBE: erosion https://t.co/enHned1acr

• https://bit.ly/437OLtH